Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib PK in Hepatic Impairment
NCT02765724Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pacritinib in myelofibrosis (MF) (4 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Pharmacokinetic Profile at 168 hours. Started Jan 2015; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02765724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765724.